149 related articles for article (PubMed ID: 30956977)
1. Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia.
Olmos I; Ibarra M; Vázquez M; Maldonado C; Fagiolino P; Giachetto G
Biomed Res Int; 2019; 2019():3163502. PubMed ID: 30956977
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.
Li LJ; Shang DW; Li WB; Guo W; Wang XP; Ren YP; Li AN; Fu PX; Ji SM; Lu W; Wang CY
Acta Pharmacol Sin; 2012 Nov; 33(11):1409-16. PubMed ID: 22820910
[TBL] [Abstract][Full Text] [Related]
3. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
[TBL] [Abstract][Full Text] [Related]
4. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study.
Ng W; Uchida H; Ismail Z; Mamo DC; Rajji TK; Remington G; Sproule B; Pollock BG; Mulsant BH; Bies RR
Ther Drug Monit; 2009 Jun; 31(3):360-6. PubMed ID: 19349931
[TBL] [Abstract][Full Text] [Related]
5. Semi-physiological Pharmacokinetic Model of Clozapine and Norclozapine in Healthy, Non-smoking Volunteers: The Impact of Race and Genetics.
Albitar O; Harun SN; Sheikh Ghadzi SM
CNS Drugs; 2024 Jul; 38(7):571-581. PubMed ID: 38836990
[TBL] [Abstract][Full Text] [Related]
6. Plasma clozapine and norclozapine in patients prescribed different brands of clozapine (Clozaril, Denzapine, and Zaponex).
Couchman L; Morgan PE; Spencer EP; Johnston A; Flanagan RJ
Ther Drug Monit; 2010 Oct; 32(5):624-7. PubMed ID: 20720516
[TBL] [Abstract][Full Text] [Related]
7. Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia.
Ismail Z; Wessels AM; Uchida H; Ng W; Mamo DC; Rajji TK; Pollock BG; Mulsant BH; Bies RR
Am J Geriatr Psychiatry; 2012 Jan; 20(1):53-60. PubMed ID: 21422906
[TBL] [Abstract][Full Text] [Related]
8. Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia.
Guitton C; Kinowski JM; Abbar M; Chabrand P; Bressolle F
J Clin Pharmacol; 1999 Jul; 39(7):721-8. PubMed ID: 10392327
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients.
González-Esquivel DF; Castro N; Ramírez-Bermúdez J; Custodio V; Rojas-Tomé S; Castro-Román R; Jung-Cook H
Arzneimittelforschung; 2011; 61(6):335-9. PubMed ID: 21827043
[TBL] [Abstract][Full Text] [Related]
10. CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients.
Doude van Troostwijk LJ; Koopmans RP; Vermeulen HD; Guchelaar HJ
Eur J Pharm Sci; 2003 Dec; 20(4-5):451-7. PubMed ID: 14659489
[TBL] [Abstract][Full Text] [Related]
11. Comedication of Valproic Acid Is Associated With Increased Metabolism of Clozapine.
Hommers L; Scharl M; Hefner G; Hohner M; Fischer M; Pfuhlmann B; Deckert J; Unterecker S
J Clin Psychopharmacol; 2018 Jun; 38(3):188-192. PubMed ID: 29620699
[TBL] [Abstract][Full Text] [Related]
12. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia.
Facciolà G; Avenoso A; Spina E; Perucca E
Ther Drug Monit; 1998 Dec; 20(6):628-30. PubMed ID: 9853978
[TBL] [Abstract][Full Text] [Related]
13. Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients.
Lee ST; Ryu S; Nam HJ; Lee SY; Hong KS
Int Clin Psychopharmacol; 2009 May; 24(3):139-44. PubMed ID: 19194306
[TBL] [Abstract][Full Text] [Related]
14. Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy.
Légaré N; Grégoire CA; De Benedictis L; Dumais A
Med Hypotheses; 2013 Jun; 80(6):689-91. PubMed ID: 23490199
[TBL] [Abstract][Full Text] [Related]
15. Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients.
Hermida J; Paz E; Tutor JC
Ther Drug Monit; 2008 Feb; 30(1):41-5. PubMed ID: 18223461
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic/pharmacodynamic model of clozapine for characterizing the relationship between accumulated exposure and PANSS scores in patients with schizophrenia.
Shang DW; Li LJ; Wang XP; Wen YG; Ren YP; Guo W; Li WB; Li L; Zhou TY; Lu W; Wang CY
Ther Drug Monit; 2014 Jun; 36(3):378-86. PubMed ID: 24342896
[TBL] [Abstract][Full Text] [Related]
17. Exploring clozapine pharmacokinetics in Tunisian schizophrenic patients: A population-based modelling approach investigating the impact of genetic and non-genetic variables.
Mansour K; Fredj NB; Ammar H; Romdhane HB; Mhalla A; Chaabane A; Chadli Z; Aouam K
Basic Clin Pharmacol Toxicol; 2024 Jun; 134(6):805-817. PubMed ID: 38599832
[TBL] [Abstract][Full Text] [Related]
18. The significance of sampling time in therapeutic drug monitoring of clozapine.
Jakobsen MI; Larsen JR; Svensson CK; Johansen SS; Linnet K; Nielsen J; Fink-Jensen A
Acta Psychiatr Scand; 2017 Feb; 135(2):159-169. PubMed ID: 27922183
[TBL] [Abstract][Full Text] [Related]
19. Disposition of clozapine and desmethylclozapine in schizophrenic patients.
Lin SK; Chang WH; Chung MC; Lam YW; Jann MW
J Clin Pharmacol; 1994 Apr; 34(4):318-24. PubMed ID: 8006199
[TBL] [Abstract][Full Text] [Related]
20. Steady-State Clozapine and Norclozapine Pharmacokinetics in Maori and European Patients.
Menkes DB; Glue P; Gale C; Lam F; Hung CT; Hung N
EBioMedicine; 2018 Jan; 27():134-137. PubMed ID: 29254680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
